FibroBiologics, Inc. FBLG
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -81.56%
- 1 year
- -87.97%
5D -0.1700 (-16.83%)
- Market cap
- 7.46M
- EPS (ttm)
- -2.51
- Shares out
- 34.66M
- Forward P/E
- -5.83
- YTD return
- -81.56%
- 1-year return
- -87.97%
- 50-day average
- 2.74
- Volume
- 25.68K
- Avg volume
- 174.21K
- Open
- 0.8148
- Previous close
- 0.84
- Day's range
- 0.8148 – 0.888
- 52-week range
- 0.62 – 9.60
- Price target
- 12.75 (+1436.1%)
Key statistics
- 200-day average
- 5.70
- Enterprise value
- 71.72M
- Price / book
- 25.93
- Free cash flow
- -470.00K
- Total cash
- 7.83M
- Total debt
- 1.56M
- Return on equity
- -267.86%
- Short % of float
- 9.48%
Fundamental scorecard
4 of 25 checks passed on FBLG’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.08 | -0.08 | 0.00 | 0.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.09 | — | — | — |
| Aug 7, 2024 | Jun 1, 2024 | -0.09 | -0.09 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 12, 2024 | Rodman & Renshaw | init | — | Buy |
| Nov 20, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 13, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 30, 2024 | HC Wainwright & Co. | init | — | Buy |
| Oct 18, 2024 | EF Hutton | main | Buy | Buy |
About FibroBiologics, Inc.
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fibrobiologics.com
News
FibroBiologics Reports Third Quarter 2026 Financial Results; Highlights Upcoming Catalysts
FibroBiologics Announces Update On Its Intellectual Property Portfolio FibroBiologics Secures European Patent Covering Methods Of Preparing Fibroblasts To Home To Tumors And Carry Oncolytic Viruses And Other Anti-Cancer Agents
FibroBiologics Reports Preclinical Data Showing FSdC Spheroids Best Preserve Disc Height In Rabbit Degenerative Disc Disease Model
Your note
Sign in to keep a note on FBLG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KHOJA HAMID | Officer | Purchase | Aug 11, 2024 | 11,250 |
| O'HEERON PETER | Chief Executive Officer | Stock Gift | Dec 8, 2024 | 5,906,650 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 5.07% | 1,756,593 | 3.69M | Sep 29, 2024 |
| Vanguard Group Inc | 2.23% | 771,444 | 1.62M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.73% | 599,760 | 1.26M | Sep 29, 2024 |
| State Street Corporation | 1.37% | 475,837 | 999.26K | Sep 29, 2024 |
| Cascade Financial Partners, LLC | 0.87% | 302,601 | 635.46K | Sep 29, 2024 |
| Northern Trust Corporation | 0.61% | 210,473 | 441.99K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 1.81% | 627,676 | 1.32M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.18% | 407,674 | 856.12K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.75% | 259,500 | 544.95K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.75% | 259,295 | 544.52K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 0.44% | 152,807 | 320.89K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.41% | 142,802 | 299.88K | Oct 30, 2024 |
